Tesamorelin (20mg)

Variant specifications

Selected product: Tesamorelin (20mg)

Declared strength: 20mg total for this specific listing. Its SKU, price, inventory, and lot documentation are maintained separately from the other strength options.

Other available strengths: Tesamorelin (10mg)

The research overview below describes the shared compound or blend. Strength-specific purchasing and documentation details apply only to the selected listing above.

Tesamorelin is a prescription peptide medication that mimics growth hormone-releasing hormone, reducing excess deep belly fat in adults with HIV-associated lipodystrophy. It is administered daily as a subcutaneous injection and works by stimulating the pituitary gland to produce natural growth hormone. [1, 2, 3]

How It Works

• GHRH analog: Binds to receptors in the pituitary gland to trigger the natural, pulsatile release of growth hormone.
• Increases IGF-1: Raises insulin-like growth factor 1 levels to promote the breakdown of visceral adipose tissue (deep stomach fat).
• Body composition: Improves fat metabolism while sparing overall body structures compared to standard weight loss tools. [1, 2, 3, 4, 5]

Uses and Dosing

• Approved indication: Treatment of excess abdominal fat in HIV-infected patients with lipodystrophy (sold under brand names like Egrifta SV). [1, 2]
• Standard dosage: Usually 1.4 mg to 2 mg injected under the skin of the stomach once daily, rotating injection sites to prevent skin irritation. [1]

Side Effects and Risks

• Common reactions: Joint stiffness, muscle pain, swelling/fluid retention, and injection-site redness or pain.
• Metabolic changes: Can alter blood sugar levels and glucose tolerance.
• Precautions: Avoided in active cancer, pituitary gland tumors, or pregnancy. [1, 2, 3]

Research References

Independent research information: [1]